Physician profile
Celeste Boeckman
NPI 1083903728
$89,584.93
in general payments reported to CMS, 2019-2025
26 companies · $43K in 2025
The $43K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $14.29 · 2022: $225 · 2023: $474 · 2024: $45K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $84K · Food and Beverage: $4,590 · Travel and Lodging: $928 · Education: $89.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83,545.00 |
| Food and Beverage | $4,590.12 |
| Travel and Lodging | $927.79 |
| Education | $89.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $59,368.22 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $26,819.81 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $707.97 | 2022-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $446.38 | 2019-2025 | |
| Amgen INC. | $376.54 | 2023-2025 | Tavneos |
| Ardelyx, INC. | $285.31 | 2023-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $204.37 | 2024-2025 | Velphoro, Velphoro |
| Vantive US Healthcare LLC | $149.11 | 2025 | Renal - Pd |
| Bayer Healthcare Pharmaceuticals INC. | $140.35 | 2024-2025 | |
| Travere Therapeutics, INC. | $125.61 | 2024-2025 | Filspari |
| Shield Therapeutics INC | $112.06 | 2025 | |
| Aurinia Pharma U.S., INC. | $110.82 | 2022-2024 | Lupkynis |
| Ani Pharmaceuticals, INC. | $104.51 | 2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $93.79 | 2019-2025 | Ultomiris |
| Vifor Pharma, INC. | $88.92 | 2022-2023 | Korsuva, Veltassa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $80.61 | 2024 | Defencath |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $78.43 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $75.33 | 2019-2020 | |
| Daiichi Sankyo INC. | $45.37 | 2024 | Injectafer |
| Opko Pharmaceuticals, LLC | $38.61 | 2022-2024 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $36.01 | 2025 | Terlivaz |
| Pfizer INC. | $27.93 | 2019 | |
| Scpharmaceuticals INC. | $21.31 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $20.23 | 2023 | Jynarque |
| Merck Sharp & Dohme LLC | $13.85 | 2019 | |
| Glaxosmithkline, LLC. | $13.48 | 2024 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Boeckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.